比较两种依洛尤单抗药物产品单次皮下给药后在体内的可利用程度。
一项开放标签、1期、单剂量、随机、平行分组研究,用于评估两种Evolocumab(AMG 145)药物产品的相对生物利用度
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two evolocumab drug products in healthy participants.
研究概览
地位
条件
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
California
-
Anaheim、California、美国、92801-2658
- Anaheim Clinical Trials
-
-
Florida
-
South Miami、Florida、美国、33143
- Quest Pharmaceutical Services - Miami Research Associates - Early Phase
-
-
Missouri
-
Springfield、Missouri、美国、65802
- QPS Bio-Kinetic
-
-
Texas
-
Dallas、Texas、美国、75247
- Fortrea Clinical Research Unit - Dallas
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Male or female, of any race, between 18 and 60 years of age, inclusive.
a. Females must not be pregnant or lactating.
-
Body mass index (BMI) between 18.0 and 32.0 kg/m^2 inclusive.
-
LDL-C level ≥ 70 mg/dL (1.8 mmol/L) and ≤ 190 mg/dL (4.9 mmol/L) at screening.
Exclusion Criteria:
- History or evidence of any clinically significant disorder, condition, or disease that in the opinion of the investigator (or designee) would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.
- History or current signs or symptoms of cardiovascular disease.
- History or evidence of clinically significant arrhythmia.
- History of hypersensitivity, intolerance, or allergy to evolocumab or its ingredients or other biological drugs.
- Uncontrolled hyperthyroidism or hypothyroidism.
- Current use or prior use of over-the-counter or other prescription medications, herbal medicines, vitamins, and supplements within 30 days or 5 half-lives prior to check-in.
- Participation in another investigational device or drug trial within the past 30 days or 5 half-lives prior to check-in.
- Have previously completed or withdrawn from this trial or any other trial investigating evolocumab, any other product directed against PCSK9, or have previously received evolocumab or PCSK9 inhibitor.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Evolocumab Drug Substance A (Test)
Participants will receive a single subcutaneous (SC) dose of evolocumab drug substance A. |
Evolocumab drug substance A will be administered SC.
其他名称:
|
|
实验性的:Evolocumab Drug Substance B (Reference)
Participants will receive a single SC dose of evolocumab drug substance B. |
Evolocumab drug substance B will be administered SC.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
从时间0外推至无穷大的浓度-时间曲线下面积 (AUCinf)(依洛尤单抗)
大体时间:第1天至第64天
|
第1天至第64天
|
|
最大观察浓度 (Cmax) 的依洛尤单抗
大体时间:第1天至第64天
|
第1天至第64天
|
|
Evolocumab 从时间 0 到最后可量化浓度时间点的曲线下面积 (AUClast)
大体时间:第1天至第64天
|
第1天至第64天
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
产生抗依洛尤单抗抗体的参与者人数
大体时间:第1天和第64天
|
第1天和第64天
|
|
第1天至第64天低密度脂蛋白胆固醇(LDL-C)效应曲线下面积(AUECDay1-Day64)
大体时间:第1天至第64天
|
第1天至第64天
|
|
前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)的血清水平
大体时间:第1天至第64天
|
第1天至第64天
|
|
发生治疗期不良事件(TEAE)的参与者人数
大体时间:第1天至第64天
|
第1天至第64天
|
|
发生严重不良事件(SAE)的参与者人数
大体时间:至第64天
|
至第64天
|
合作者和调查者
赞助
调查人员
- 研究主任:MD、Amgen
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD 共享时间框架
Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.
IPD 共享访问标准
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.